

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

Claims 1-20 (Canceled)

Claim 21. (Currently Amended) A method of obtaining a target polypeptide having a bindable epitope from a product, the method comprising:

co-expressing a target polypeptide and a multivalent binding polypeptide in a product of a non-human transgenic mammal,
~~contacting a product which comprises a target polypeptide having a bindable epitope with a transgenically produced multivalent binding polypeptide,~~
wherein the transgenically produced multivalent binding polypeptide comprises a first binding moiety which specifically binds the bindable epitope of the target polypeptide and a second binding moiety which specifically binds a matrix, ~~to thereby provide a reaction mixture;~~
contacting ~~the reaction mixture~~ the product with a matrix which specifically binds the second binding moiety of the multivalent binding polypeptide; and
removing reaction mixture which does not bind to the matrix, to thereby obtain the target polypeptide from the product; and
wherein the reaction mixture is substantially fluid; and
wherein the first binding moiety of the multivalent binding polypeptide is an antibody or functional fragment thereof which binds the bindable epitope of the target polypeptide.

Claim 22. (Previously Presented) The method of claim 21, wherein the second binding moiety of the multivalent binding polypeptide is a cellulose binding domain (CBD), or a chemically functional fragment thereof.

Claim 23. (Currently Amended) The method of claim 21, wherein the target polypeptide is a

receptor and the first binding moiety of the multivalent binding polypeptide is a ligand which binds the bindable epitope of the receptor.

Claim 24. (Canceled)

Claim 25. (Currently Amended) A method of obtaining a target polypeptide having a bindable epitope from the milk product of a first non-human transgenic mammal, the method comprising:

contacting [[a]]the product which comprises a target polypeptide having a bindable epitope with a product of a second non-human transgenic mammal comprising a transgenically produced multivalent binding polypeptide, wherein the transgenically produced multivalent binding polypeptide comprises a first binding moiety which specifically binds the bindable epitope of the target polypeptide and a second binding moiety which specifically binds a matrix, to thereby provide a reaction mixture; contacting the reaction mixture with a matrix which specifically binds the second binding moiety of the multivalent binding polypeptide; and removing reaction mixture which does not bind to the matrix, to thereby obtain the target polypeptide from the product; and wherein the reaction mixture is substantially fluid; and wherein the first binding moiety of the multivalent binding polypeptide is an antibody or functional fragment thereof which binds the bindable epitope of the target polypeptide; and, wherein the transgenically produced multivalent binding polypeptide is produced in the milk of a second non-human transgenic mammal.

Claim 26. (Canceled)

Claim 27. (Currently Amended) A method of obtaining a target polypeptide having a bindable epitope from the milk of a first non-human transgenic mammal, the method comprising:

contacting the milk which comprises said target polypeptide having a bindable epitope with milk of a second non-human transgenic animal comprising a transgenically produced multivalent binding polypeptide, wherein said multivalent binding polypeptide comprises a first binding moiety which specifically binds the bindable epitope of said target polypeptide and a second binding moiety which specifically binds a matrix, to thereby provide a reaction mixture;

contacting said reaction mixture with a matrix which specifically binds said second binding moiety of said multivalent binding polypeptide; and removing reaction mixture which does not bind to the matrix, to thereby obtain said target polypeptide from the milk;

wherein said reaction mixture is substantially fluid; and wherein said transgenically produced multivalent binding polypeptide is produced in milk from a second non-human transgenic mammal; and, wherein said first binding moiety of said multivalent binding polypeptide is an antibody or chemically functional fragment thereof which binds the bindable epitope of the target polypeptide.

Claim 28. (Previously Presented) The method of claim 27, wherein said second binding moiety of said multivalent binding polypeptide is a cellulose binding domain (CBD), or a chemically functional fragment thereof.

Claim 29. (Currently Amended) The method of claim 27, wherein said target polypeptide is a receptor and said first binding moiety of said multivalent binding polypeptide is a ligand which binds said bindable epitope of the receptor.

Claim 30-42. (Canceled)

Claim 43. (Previously Presented) The method according to claim 21 or 27, wherein said target polypeptide is an antibody.

Claim 44. (New) The method according to claim 1, wherein the product is milk of the non-human transgenic mammal.